Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Figlin

Showing results (21-30 of 89) with videos related to

Pageof 9
Sort By:
Cancer Investigation|January 1, 1995
Immunologic approaches to the treatment of cancerR A Figlin, B J Gitlitz, A Belldegrun
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1993
Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trialN J Vogelzang, A Lipton, R A Figlin
Journal of Biological Response Modifiers|August 1, 1987
Phase II study of betaseron (beta ser17-interferon) as treatment of advanced malignant melanomaG P Sarna, R A Figlin, M Pertcheck
Chest|August 1, 1989
Pulmonary toxicity of recombinant human tumor necrosis factorJ H Kuei, D P Tashkin, R A Figlin
Seminars in Oncology|April 1, 1996
The biology of the cytokine sequence cascadeJ K Fraser, M C Lill, R A Figlin
Seminars in Urologic Oncology|May 17, 2001
Vaccine and gene therapy of renal cell carcinomaB J Gitlitz, A S Belldegrun, R A Figlin
Current Opinion in Molecular Therapeutics|November 22, 2001
Technology evaluation: interleukin-2 gene therapy for the treatment of renal cell carcinomaR A Figlin, S E Parker, H M Horton
The New England Journal of Medicine|January 5, 2002
Nephrectomy and interleukin-2 for metastatic renal-cell carcinomaA J Pantuck, A S Belldegrun, R A Figlin
Annals of Internal Medicine|October 15, 1989
Tumor necrosis factor induces hemorrhagic necrosis of a sarcomaP A Robertson, H J Ross, R A Figlin
Cancer Treatment Reports|March 1, 1985
Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trialR A Figlin, J B deKernion, J Maldazys, et al.
Pageof 9

Showing results (21-30 of 89) with videos related to

Sort By:
Pageof 9
Cancer Investigation|January 1, 1995
Immunologic approaches to the treatment of cancerR A Figlin, B J Gitlitz, A Belldegrun
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1993
Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trialN J Vogelzang, A Lipton, R A Figlin
Journal of Biological Response Modifiers|August 1, 1987
Phase II study of betaseron (beta ser17-interferon) as treatment of advanced malignant melanomaG P Sarna, R A Figlin, M Pertcheck
Chest|August 1, 1989
Pulmonary toxicity of recombinant human tumor necrosis factorJ H Kuei, D P Tashkin, R A Figlin
Seminars in Oncology|April 1, 1996
The biology of the cytokine sequence cascadeJ K Fraser, M C Lill, R A Figlin
Seminars in Urologic Oncology|May 17, 2001
Vaccine and gene therapy of renal cell carcinomaB J Gitlitz, A S Belldegrun, R A Figlin
Current Opinion in Molecular Therapeutics|November 22, 2001
Technology evaluation: interleukin-2 gene therapy for the treatment of renal cell carcinomaR A Figlin, S E Parker, H M Horton
The New England Journal of Medicine|January 5, 2002
Nephrectomy and interleukin-2 for metastatic renal-cell carcinomaA J Pantuck, A S Belldegrun, R A Figlin
Annals of Internal Medicine|October 15, 1989
Tumor necrosis factor induces hemorrhagic necrosis of a sarcomaP A Robertson, H J Ross, R A Figlin
Cancer Treatment Reports|March 1, 1985
Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trialR A Figlin, J B deKernion, J Maldazys, et al.
Pageof 9